- Analytics
- Trading News
Trading News
Boeing 737 MAX Hits 38 Jets Per Month| Latest 2025 Update
After Years of Turmoil, Boeing Reaches FAA Production Limit. Boeing has produced 38 737 MAX jets in May 2025 — the first time it's met that production cap since late 2020. This milestone signals a potential...
Trump’s New Tariff Threat on Steel and Aluminum
U.S. President Donald Trump has once again threatened to double tariffs—this time on steel and aluminum—raising them to 50%. But unlike previous rounds of trade drama, markets barely blinked. Investors...
Why Copper Prices Are Rising in 2025
Copper prices are rising again. In early 2025, we’ve seen copper trading close to $4.70 per pound. That’s a big jump compared to the lows we saw in mid-2023. The World Needs More Copper Than It Has...
Why Is Netflix Stock Going Up? | Latest 2025 Update
Netflix stock is on the rise, and many investors are asking the same question: why is Netflix going up? The answer lies in strong earnings, smart business moves, and big changes in how Netflix makes money....
“Big Beautiful Bill” - Key Takeaways
House Republicans have moved forward with a major legislative package called the “Big Beautiful Bill.” This bill combines a debt ceiling increase with changes to taxes, border policies, and spending...
Trump vs Walmart
Key Point: growing clash between politics and retail margins could spell new volatility for consumer stocks—and potential inflation surprises. Over the weekend, Trump publicly attacked Walmart for planning...
Skechers Sells Out at a Discount—3G Capital Buys the Panic
Skechers is undervalued, and 3G Capital knows it. In a surprise move, Skechers has agreed to go private in a $9.42 billion buyout led by 3G Capital. The deal, valued at $63 a share, represents a 28% premium...
Tesla Posts One of Worst Quarters Since 2022
Automotive revenue, which has always been Tesla’s main driver, fell 20% year over year. They sold 337,000 cars, down 13%, and that’s after price cuts have already hurt their margins. Not only are Teslas...
How to Trade JNJ: Stelara Decline and New Product Hopes
Johnson & Johnson (JNJ) drug Stelara, which brought in more than $11 billion last year, is under threat from biosimilars in both the U.S. and Europe. Which directly hits JNJ’s core pharma revenue and...
Explore our
Trading Conditions
- Spreads from 0.0 pip
- 30,000+ Trading Instruments
- Instant Execution
Ready to Trade?
Open Account